These compounds are selective for EZH2 over other SET domain methyltransferases, are able to inhibit catalytic activity of both wild-type and lymphoma-associated mutants of EZH2 and reduce the cellular level of H3K27me3. This evidence concerns the gene EZH2 and lymphoma.